The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients

Tim J. Kruser, Anne M. Traynor, Deric L. Wheeler

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

A Phase II study of the Src family kinase (SFK) inhibitor dasatinib was recently reported in molecularly unselected patients with metastatic NSCLC. SFK inhibition has a strong rationale as a clinical strategy in NSCLC. The reviewed study unfortunately showed disappointing activity as monotherapy in this molecularly unselected patient cohort and toxicity in terms of pleural effusion was problematic. Therefore, dasatinib as monotherapy in this setting does not appear promising. Nonetheless, the reviewed study may be used in conjunction with other studies of dasatinib in NSCLC to identify patients more likely to benefit from dasatinib either as monotherapy or in combination with other agents. Future studies of dasatinib in NSCLC should examine the agent in combination with EGFR inhibitors and/or cytotoxic chemotherapies.

Original languageEnglish (US)
Pages (from-to)305-307
Number of pages3
JournalExpert Opinion on Investigational Drugs
Volume20
Issue number2
DOIs
StatePublished - Feb 2011

Keywords

  • NSCLC
  • clinical trial
  • dasatinib
  • small molecules

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients'. Together they form a unique fingerprint.

Cite this